A Label-Free, Multi-Omic Study to Qualitatively and Quantitatively Characterize the Effects of a Glucosylceramide Inhibitor on Obesity

This application note describes a label-free, multi-omic approach to investigate the effects of a glucosylceramide inhibitor for the treatment of obesity. Progenesis® QI and Progenesis QI Proteomics Software enables a seamless workflow, from LC-MS data processing and database searching to pathway interrogation, implicating carbohydrate metabolism, and molecular transport networks in the compound’s mechanism of action.